FORE Biotherapeutics develops targeted cancer therapies for unaddressed tumor mutations, advancing investigational plixorafenib to inhibit a broad range of BRAF alterations.
FORE Biotherapeutics develops targeted cancer therapies for unaddressed tumor mutations, advancing investigational plixorafenib to inhibit a broad range of BRAF alterations.